Teva Pharmaceutical Industries Ltd.

First Quarter 2019 Results

May 2, 2019

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; the uncertainty of commercial success of AJOVY® or AUSTEDO®; competition from companies with greater resources and capabilities; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our products, both from competing products and increased regulation; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; our ability to take advantage of high-value opportunities; the difficulty and expense of obtaining licenses to proprietary technologies; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: failure to effectively execute our restructuring plan announced in December 2017; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the ongoing review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets ;
- compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S.; governmental investigations into selling and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2019 and in our Annual Report on Form 10-K for the year ended December 31, 2018, including in the sections captioned "Risk Factors" and "Forward-looking statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures as defined by SEC rules. Please see our press release reporting our 2019 first quarter financial results, as well as our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, for a reconciliation of the GAAP results to the adjusted non-GAAP figures. The non-GAAP data presented by Teva are the results used by Teva's management and board of directors to evaluate the operational performance of the company, to compare against the company's work plans and budgets, and ultimately to evaluate the performance of management. Teva provides such non-GAAP data to investors as supplemental data and not in substitution or replacement for GAAP measure, because management believes such data provides useful information to investors. A reconciliation of forward-looking non-GAAP estimates to the corresponding GAAP measures is not being provided due to the unreasonable efforts required to prepare it.

Kåre Schultz

Chief Executive Officer

Quarterly Highlights

Results

- Revenues of $4.3 billion
- GAAP diluted loss per share of $0.10 and non-GAAP diluted EPS of $0.60
- Non-GAAP EBITDA of $1.15 billion
- Free cash flow of $0.36 billion

Operations

- Stable global generics business supported by new launches
- AJOVY® and AUSTEDO® growth continues
- Loss of exclusivity in COPAXONE® and ProAir®
- AJOVY® received EU approval in April 2019


Expense and Debt Reduction

- Spend base reduction continues to progress; on track to achieve 2-year target of $3 billion
- Executing site consolidation
- Net debt decreased by $0.5 billion to $26.7 billion
- $1.6 billion scheduled for repayment in 2019

Reaffirming 2019 Financial Outlook

Spend Base Restructuring Progress

$ billions



- Last 4 quarters spend base level of $13.8 billion, reflecting $2.5 billion spend reduction vs. 2017
- Annualization of Q1 2019 spend level indicates that Teva will achieve the restructuring target
- FTE reduced by ~10,400 since the start of the restructuring plan

*Spend Base = Non-GAAP COGS + Operating Expenses (including other income/expenses)


AJOVY®

AJOVY™ Weekly Normalized TRx Count



Source: IQVIA NPA TRx (weekly), normalized

AJOVY™ NBRx Share*



**monthly NBRx share estimated from weekly NBRx data*

Source: IQVIA NPA MD (weekly)


Highlights

- $20M in Net Sales for Q1 2019
- Normalized TRx Share* of ~23%
- ~8% of YTD AJOVY™ TRx's are Quarterly dosing
- Over 10K unique health care practitioners have prescribed AJOVY™
- AJOVY™ now has access to over 67% of commercial lives

**for week ending 03/29/2019*


AUSTEDO®

AUSTEDO® TRx Count Per Quarter



Source: IQVIA U.S. NPA Audit

AUSTEDO® Revenues By Quarter ($ million)




Source: Company Information

Highlights

- $74M in Net Sales for Q1 2019
- $204M in Net Sales for 2018
- Over 18K prescriptions dispensed in Q1 2019
- Favorable national formulary coverage
  - Commercial: 89%
  - Medicare Part D: 85%


COPAXONE® (U.S. only)

COPAXONE® TRx Count Per Quarter ('000s)



Source: IQVIA NPA TRx (monthly)

COPAXONE® Revenues By Quarter ($ million)



Source: Company Information

Highlights

- $194M in Net Sales for Q1 2019
- COPAXONE® Q1 2019 exit TRx share of total U.S. MS market ~17.9% vs. 2018 share ~21.8%
- COPAXONE® 40mg share of the 40mg glatiramer acetate market ~67% (March 2019) vs. ~75% share (December 2018)

Michael McClellan

Chief Financial Officer

Q1 2019 Summary

$ millions, except EPS	Q1 2019	Q1 2018	Q1 2019	Q1 2018
	GAAP		Non-GAAP	
Revenues	4,295	5,065	4,295	5,065
Operating income (loss)	134	1,525	1,019	1,435
Net income (loss) attributable to Teva	(105)	1,120	654	954
Earnings (loss) per share ($)	(0.10) 1,090M shares	1.03 1,020M shares	0.60 1,093M shares	0.94 1,020M shares

Q1 2019 Non-GAAP Adjustments

$ millions	Q1 2019	Highlights
Impairment*	364	Mainly U.S. intangible assets and product rights ($348M)
Amortization	283	Quarterly run-rate
Legal settlements	57	
Contingent consideration*	35	BENDEKA exclusivity extension
Equity compensation plans	34	
Restructuring	32	
Lenalidomide	19	Intangibles impairment net of change in contingent consideration
Other items	59	
Minority	(8)	
Income tax	(116)	
Total adjustments	**759**	

* Excluding Lenalidomide

Q1 2019 Non-GAAP Summary

$ billions, except EPS	Q1 2019	Q1 2018	Change
Revenues	4.3	5.1	*(15%)*
Gross profit	2.1 50.1%	2.6 51.7%	*(18%)*
Operating income	1.0 23.7%	1.4 28.3%	*(29%)*
EBITDA	1.2	1.6	*(27%)*
Net income	0.7	1.0	*(36%)*
EPS ($)	0.60 1,093M shares	0.94 1,020M shares	*(36%)*
Free cash flow*	**0.4**	**1.9**	***(81%)***
Total cash generated**	**0.3**	**2.5**	***(87%)***

* Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables

** Q1 2018 cash generated includes $0.7b of WH EU divestiture proceeds

Q1 2019 Foreign Exchange Impact

$ millions	Q1 2019	Q1 2018	Diff	FX Effect	Diff net FX
Revenues	4,295	5,065	(770)	(177)	(593)
Operating income **GAAP**	134	1,525	(1,391)	(49)	(1,342)
Operating income **Non-GAAP**	1,019	1,435	(416)	(58)	(358)


Revenues by Activity and Geographical Area

$ millions	Q1-18	Q2-18	Q3-18	Q4-18	Q1-19
North America Segment	**2,531**	**2,263**	**2,265**	**2,238**	**2,047**
Generic Medicines	1,088	947	922	1,099	966
COPAXONE	476	464	463	356	208
AJOVY	-	-	-	3	20
TREANDA and BENDEKA	181	160	161	140	122
ProAir*	130	115	107	45	59
QVAR	107	30	36	9	64
AUSTEDO	30	44	62	68	74
Distribution	331	320	333	363	379
Other	188	183	181	154	155
Europe Segment	**1,442**	**1,328**	**1,212**	**1,204**	**1,264**
Generic Medicines	997	907	845	844	919
COPAXONE	153	140	124	118	114
Respiratory products	113	106	93	90	91
Other	179	175	150	152	140
International Markets Segment	**750**	**789**	**726**	**740**	**668**
Generic Medicines	488	537	498	499	441
COPAXONE	16	22	14	20	13
Distribution	153	154	149	146	151
Other	93	76	65	75	62
Other	**342**	**321**	**326**	**377**	**317**
Total Teva	**5,065**	**4,701**	**4,529**	**4,559**	**4,295**

* Excluding ProAir AG

Free Cash Flow

$ millions




	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019
CAPEX, Net**	(46)	(129)	(119)	(208)	(114)
Securitization re-class	444	526	402	363	362
Operating cash flow	1,496	162	421	367	112

* Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

** Capex, net – gross capital expenditure, net of assets sales.

Liquidity

$ billions



	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019
Net Debt / EBITDA MAT	4.53	4.63	4.79	5.10	5.45
Leverage	60%	61%	61%	65%	64%

* According to Teva's credit agreement covenant ratio - adjusted ratio excludes EBITDA contribution of the divested women's heath business for the relevant test period; Teva's Net Debt/EBITDA covenants were amended to 6.25x for Q1-Q4 2019.

Reaffirming 2019 Non-GAAP Outlook

$ billions, except EPS	2019 Outlook	FY 2018
Revenues	17.0-17.4	18.9
Operating Income	3.8 – 4.2	4.7
EBITDA	4.4 – 4.8	5.3
EPS ($)	2.20-2.50 1,096M shares	2.92 1,024M shares
Free Cash Flow*	1.6-2.0	3.7


* Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables

Q&A

Additional Information

Quarterly EBITDA


$ millions



EBITDA is based on non-GAAP operating income (which excludes amortization and certain other items) and excludes depreciation expenses

Q1 2019 Revenues Trend

$ millions




Spend Base Trend (Non-GAAP)

$ millions	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019
COGS	2,447	2,362	2,268	2,231	2,145
S&M	682	634	634	768	602
R&D	289	281	243	289	255
G&A	322	292	284	330	280
Other income	(110)	(106)	(4)	(5)	(6)
Total	**3,630**	**3,463**	**3,425**	**3,613**	**3,277**


Quarterly Non-GAAP Operating Income

$ millions




Quarterly Non-GAAP Operating Income

$ millions



Quarterly Non-GAAP Operating Income

$ millions



Quarterly GAAP Income Statement

$ millions, except EPS	Q1-19	Q1-19 Margins	Q1-18	Q1-18 Margins	Change
Revenues	**4,295**		**5,065**		***(15%)***
COGS	2,440	56.8%	2,750	54.3%	*(11%)*
Gross profit	**1,856**	**43.2%**	**2,315**	**45.7%**	***(20%)***
R&D	261	6.1%	317	6.3%	*(18%)*
S&M	648	15.1%	738	14.6%	*(12%)*
G&A	292	6.8%	329	6.5%	*(11%)*
Legal settlements and loss contingencies	57	1.3%	(1,278)	(25.2%)	*(104%)*
Impairments, restructuring and others	470	10.9%	887	17.5%	*(47%)*
Other income	(6)	(0.1%)	(203)	(4.0%)	*(97%)*
Operating income	**134**	**3.1%**	**1,525**	**30.1%**	***(91%)***
Finance exp.	218	5.1%	271	5.4%	*(19%)*
Tax	9	(10.8%)	46	3.7%	*(80%)*
Minority and share in profit (loss)	12	0.3%	88	1.7%	*(87%)*
Net income attributable to Teva	**(105)**	**(2.4%)**	**1,120**	**22.1%**	***(109%)***
Dividends on preferred shares	-		65		
Net income attributable to ordinary shareholders	**(105)**		**1,055**		
# of shares (diluted, millions)	1,090		1,020		
Earnings (loss) per share ($)	**(0.10)**		**1.03**		***(109%)***

Some amounts may not sum due to rounding


Consolidated Balance Sheet

$ billions	Mar 31, 2019	Dec 31, 2018	Diff
Cash and Cash Equivalents	2.0	1.8	*0.2*
AR Trade	5.1	5.8	*(0.7)*
Pre-paid Expenses and Other Current Assets	2.1	1.5	*0.6*
Inventory	4.8	4.7	*0.1*
Fixed Assets	6.8	6.9	*(0.1)*
Intangible Assets	13.2	14.0	*(0.8)*
Goodwill	24.8	24.9	*(0.1)*
Other Long Term Assets	1.1	1.1	*0.0*
Total Assets	59.9	60.7	***(0.8)***
AP Trade	1.8	1.9	*(0.1)*
SR&A	6.2	6.7	*(0.5)*
AP Other	3.3	3.5	*(0.3)*
Total Debt (ST+LT)	28.6	28.9	*(0.3)*
Other Long Term Liabilities	4.2	3.9	*0.3*
Minority	1.1	1.1	*0.0*
Teva Shareholders' Equity	14.7	14.7	*0.0*
Total Liabilities & Equity	59.9	60.7	***(0.8)***

Some amounts may not sum due to rounding

Q1 2019 Net Debt Movements

$ billions



Gross Debt	28.9	28.6
Cash Balance	1.8	2.0

* Net Debt = Gross Debt – Cash Balance

Current Debt Structure (as of March 31, 2019)

